IQLT - ETF AI Analysis
Top Page
iShares MSCI Intl Quality Factor ETF (IQLT)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Quality Leaders in Top Holdings
Several major positions, such as ASML and Roche, have delivered strong or steady performance, helping support the fund’s overall returns.
Broad International Diversification
Holdings spread across many countries and sectors, with no single country or industry dominating, help reduce the impact of local or sector-specific downturns.
Negative Factors
Mixed Performance Among Top Holdings
Some large positions, including Allianz, Shell, AstraZeneca, Nestlé, and Zurich Insurance Group, have shown weak or negative performance, which can drag on the fund.
Heavy Financial Sector Exposure
A sizable allocation to financial stocks means the ETF may be more sensitive to interest rate changes and financial sector stress.
Moderate Expense Ratio
The fund’s expense ratio is not especially low for a large ETF, so fees may slightly reduce long-term returns compared with the cheapest alternatives.
IQLT vs. SPDR S&P 500 ETF (SPY)
AUM12.62B
RegionDeveloped Markets
Expense Ratio0.30%
Beta0.75
IssueriShares
Inception DateJan 13, 2015
Dividend Yield2.18%
Asset ClassEquity
Index TrackedWorld ex USA Sector Neutral Quality
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,437,028
30 Day Avg. Volume2,751,915
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
54.79Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering291
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IQLT Summary
IQLT is the iShares MSCI Intl Quality Factor ETF, which follows the MSCI World ex USA Sector Neutral Quality index. It invests in “high-quality” companies from developed countries outside the U.S., focusing on firms with strong finances and steady earnings. The fund holds well-known names like Nestlé and AstraZeneca, and spreads money across many sectors such as financials, industrials, and technology. Someone might invest in IQLT to diversify beyond the U.S. and seek long-term growth from solid international companies. A key risk is that international stock prices can go up and down with global markets and currency moves.
How much will it cost me?The iShares MSCI Intl Quality Factor ETF (IQLT) has an expense ratio of 0.30%, which means you’ll pay $3 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a specific strategy of selecting high-quality international stocks, which requires more specialized research and management.
What would affect this ETF?The iShares MSCI Intl Quality Factor ETF (IQLT) could benefit from continued global economic growth and increased demand for high-quality companies in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare. However, it may face challenges from rising interest rates, which could pressure profitability in certain sectors, and geopolitical risks or regulatory changes in key regions that could impact its top holdings like ASML, Shell, and Nestlé. Diversification across sectors and countries helps mitigate some risks but does not eliminate them entirely.
IQLT Top 10 Holdings
IQLT leans heavily on Europe and other developed markets outside the U.S., and its story right now is a tug-of-war between a few winners and several sluggish giants. ASML is doing much of the heavy lifting, with rising longer-term momentum that helps offset weakness elsewhere. Shell has also been a steady engine, adding some energy to returns. But big financial and healthcare names like Allianz, Zurich Insurance, Roche, and Nestlé have been lagging, acting more like a brake than an accelerator on the fund’s overall performance.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 6.22% | $781.58M | €485.12B | 119.99% | 76 Outperform | |
| Shell (UK) | 2.62% | $329.34M | £191.74B | 48.20% | 73 Outperform | |
| Allianz | 2.44% | $305.98M | €142.88B | 15.70% | 67 Neutral | |
| Novartis AG | 2.37% | $297.84M | CHF222.29B | 41.43% | 80 Outperform | |
| AstraZeneca | 2.20% | $276.62M | $316.55B | 52.18% | 80 Outperform | |
| Roche Holding AG | 2.15% | $270.00M | $318.75B | 31.82% | 73 Outperform | |
| ABB Ltd | 2.01% | $252.38M | CHF130.82B | 78.40% | 78 Outperform | |
| Nestlé SA | 2.00% | $250.65M | CHF200.06B | -4.74% | 71 Outperform | |
| Zurich Insurance Group | 1.62% | $202.98M | CHF81.68B | 1.75% | 78 Outperform | |
| Tokio Marine Holdings | 1.54% | $193.04M | ¥13.50T | 29.98% | 66 Neutral |
IQLT Technical Analysis
Positive
―
Price Trends
47.44
Positive
46.46
Positive
44.84
Positive
Market Momentum
0.21
Negative
62.38
Neutral
94.90
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IQLT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 46.30, equal to the 50-day MA of 47.44, and equal to the 200-day MA of 44.84, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 62.38 is Neutral, neither overbought nor oversold. The STOCH value of 94.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IQLT.
IQLT Peer Comparison
Comparison Results
Performance Comparison
IQLT
iShares MSCI Intl Quality Factor ETF
48.54
10.20
26.60%
VEA
Vanguard FTSE Developed Markets ETF
―
―
―
SCHF
Schwab International Equity ETF
―
―
―
SPDW
SPDR Portfolio Developed World ex-US ETF
―
―
―
IDEV
iShares Core MSCI International Developed Markets ETF
―
―
―
DFAI
Dimensional International Core Equity Market ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents